NUS1 and liver cancer: We also found that, in HepG2 cells, NgBR overexpression significantly decreases the sensitivity of liver cancer cells to sorafenib at doses of either 5 μm or 10 μm (Figures 4C, D), and decreases rates of apoptosis following sorafenib (5 μm or 10 μm) treatment (Figure 4E).